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The Editorial on the Research Topic
Biology-Driven Targeted Therapy of Pediatric Soft-Tissue and Bone Tumors: Current 
Opportunities and Future Challenges
Sarcomas constitute a large and diverse group of malignant neoplasias and the predominant group of 
non-CNS-related solid tumors in childhood and adolescence (1). Recent advances in the understand-
ing of the genetic and biological basis of pediatric soft tissue and bone tumors, especially owing to the 
advent of “omics” technologies, have led to an exponential increase in the current knowledge on the 
genetic and cellular pathomechanisms that drive these diseases (2).
This offers the unprecedented opportunity to develop and implement targeted therapies, such 
as monoclonal antibodies, small molecules, and immunotherapies in standard and/or personalized 
treatment regimens (2). However, to date, only a few examples document a successful translation 
of discoveries from the bench to the bedside, which significantly improved patient outcome while 
having little adverse effects (3, 4). Recent reviews (5) and international expert congresses further 
emphasize the urgent need for a more rapid and especially more successful translational process (6–8) 
(Kovar et al., Schäfer et al.).
This Frontiers Research Topic entitled “Biology-driven targeted therapy of pediatric soft-tissue and 
bone tumors: current opportunities and future challenges” was dedicated to this aspect and provided 
a transdisciplinary forum for researchers working at the interfaces between basic cell biology, tumo-
rigenesis, and personalized medicine. Many excellent researchers have contributed to this topic now 
covering the most common but also rare sarcoma entities of this age group, such as osteosarcoma, 
Ewing sarcoma, rhabdomyosarcoma, and epithelioid sarcoma.
In order to accelerate the development of novel targeted therapeutics, suitable genetically 
engineered animal models and xenograft models are required. In this regard, Geier et al. discuss 
preclinical human tumor xenograft models of pediatric sarcomas that may be used practically to 
identify novel agents and how “omics” approaches may be implemented for identification of novel 
biomarkers, which can discriminate sensitive and resistant tumors to these agents. Since the ultimate 
goal of anticancer therapy is to kill cancer cells, it is important to assess in detail the modes of cell 
death in preclinical models. Rello-Varona et al. survey different modes of cell death and propose 
standards of how to adequately assess them, which is especially important in such a heterogeneous 
group of tumor entities such as human sarcomas.
February 2016 | Volume 6 | Article 392
Grünewald and Fulda Targeted Therapy of Pediatric Sarcomas
Frontiers in Oncology | www.frontiersin.org
Osteosarcoma is the most common pediatric bone cancer 
(1). Sampson et  al. discuss current knowledge on the role of 
micro RNAs (miRNAs) and their target genes in osteosarcoma 
and evaluate their potential use as therapeutic agents. They also 
summarize the efficacy of inhibition of oncogenic miRNAs or 
expression of tumor suppressor miRNAs in preclinical models of 
osteosarcoma (Sampson et al.).
Ewing sarcoma is the second most common pediatric bone-
associated sarcoma (1). Since its discovery in 1921 by James 
Ewing, the precise histogenesis of Ewing sarcoma remains enig-
matic (9). Despite this histogenetic uncertainty, Ewing sarcoma is 
genetically well characterized by the presence of pathognomonic 
EWSR1-ETS gene fusions (usually EWSR1-FLI1) (10), which 
drive this disease by acting as oncogenic transcription factors 
(10). In their review, Cidre-Aranaz and Alonso assess five major 
EWSR1-FLI1 target genes, their signaling pathways, and shed 
light on how these pathways could be exploited therapeutically. 
Indeed, earlier work showed that some EWSR1-FLI1 target genes 
are very specifically expressed in Ewing sarcoma relative to nor-
mal tissues (11), thus possibly constituting attractive targets for 
(immuno)-therapeutic intervention. In accordance, subsequent 
experiments showed that IL2 transgenic Ewing sarcoma cells 
elicit tumor-specific T and NK cell responses in vitro and in vivo 
(12). In a subsequent study, Reuter et al. now investigate the role 
of immunostimulation by OX40 ligand (also known as CD252 
or tumor necrosis factor ligand family member 4) transgenic 
Ewing sarcoma cells. The authors found that OX40L expression 
in Ewing sarcoma cells enhanced immune stimulation, suggest-
ing that the OX40/OX40L pathways should be considered in 
the design of immunotherapies against Ewing sarcoma (Reuter 
et  al.). However, immunotherapeutic advances are not limited 
to Ewing sarcoma. Roberts et al. provide exiting new insights in 
immunotherapy of Ewing sarcoma and other pediatric sarcomas 
and point out the concept of integrating antibody-based and 
cell-based immunotherapy into an overall treatment strategy of 
sarcoma.
An innovative alternative approach for treatment of Ewing 
sarcoma is targeting the tumor’s micro-environment, instead 
of targeting the tumor cells directly. In fact, bone lesions from 
primary or metastatic Ewing sarcoma are characterized by 
extensive bone remodeling and osteolysis. Redini and Heymann 
expand on this important aspect and propose targeting the bone 
tumor micro-environment in Ewing sarcoma using osteoclast 
inhibitors, such as bisphosphonates and antagonists of receptor 
activator of NF-kappa B ligand (RANKL). In addition to this, 
Deel et al. summarize the known molecular alterations within 
the Hippo pathway in sarcomas and highlight how several 
pharmacologic compounds have shown activity in modulating 
Hippo components, providing proof-of-principle that Hippo 
signaling may be harnessed for therapeutic application in 
sarcomas.
Rhabdomyosarcomas are the most common soft tissue 
tumors of childhood (1) and constitute a heterogeneous 
group of cancers with myogenic differentiation featuring 
diverse cytogenetic and mutational aberrations (7). Hettmer 
et  al. describe two disease-relevant mouse myogenic tumor 
models driven either by oncogenic Kras in p16p19null or by a 
mutant Smoothened allele. In line with this, Ridzewski et al. 
explore the therapeutic value of four Smoothened inhibitors in 
four different rhabdomyosarcoma cell lines. They found that 
some inhibitors induced strong proapoptotic and antiprolif-
erative effects in some rhabdomyosarcoma cell lines, while 
others paradoxically induced cellular proliferation at certain 
concentrations (Ridzewski et al.). Because of this heterogene-
ous response, the authors propose to conduct pretesting of 
Smoothened inhibitors in patient-derived short-term rhab-
domyosarcoma cultures or patient-derived xenograft mouse 
models before applying these drugs to patients (Ridzewski 
et  al.). In an accompanying article, Schott et  al. provide 
evidence that oncogenic RAS mutants confer resistance of 
RMS13 rhabdomyosarcoma cells to oxidative stress-induced 
ferroptotic cell death, which has important implications for 
the development of targeted therapies for rhabdomyosarcoma 
and which might at least partially explain heterogeneous 
responses on drug treatment depending on the RAS mutation 
status.
Noujaim et al. summarize clinically relevant biomarkers (e.g., 
SMARCB1, CA125, dysadherin, and others) with respect to tar-
geted therapeutic opportunities for epithelioid sarcoma, which 
is a soft tissue sarcoma of children and young adults for which 
the preferred treatment for localized disease is wide surgical 
resection. However, current treatment regimens for epithelioid 
sarcoma still lack systematic coherence, and medical management 
is to a great extent undefined, which is why especially for patients 
with regional and distal metastases, the development of targeted 
therapies is greatly desired (Noujaim et al.). Noujaim et al. also 
examine the role of EGFR, mTOR, and polykinase inhibitors (e.g., 
sunitinib) in the management of local and disseminated disease. 
The authors propose to build a consortium of pharmaceutical, 
academic, and non-profit collaborators so that a roadmap can be 
developed toward effective biology-driven therapies of epithelioid 
sarcoma (Noujaim et al.). We believe that this Frontiers Research 
Topic has provided an excellent platform on which such consortia 
can be built on.
We anticipate that the data presented in the aforementioned 
original and review articles will be of great value for the scientific 
community to ultimately improve patient care and outcome. The 
success of this Frontiers Research Topic would not have been pos-
sible without the outstanding contribution of excellent scientists 
that served either as peer reviewers or additional guest associate 
editors.
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